To provide more evidence of the prognostic value of the RB-LOH signature, we evaluated publicly available data from an independent cohort of 381 patients with advanced HR+/HER2- breast cancer treated with endocrine therapy and a CDK4/6 inhibitor at the Memorial Sloan Kettering Cancer Center (MSK)26. This evidence concerns the gene HR and breast carcinoma.